Drug Profile
TRV 734
Alternative Names: TRV-734Latest Information Update: 10 Apr 2023
Price :
$50
*
At a glance
- Originator Trevena
- Class Analgesics; Drug withdrawal therapies; Small molecules
- Mechanism of Action Beta arrestin inhibitors; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Opioid-related disorders
- Discontinued Pain
Most Recent Events
- 10 Apr 2023 3772973; SEC Filing April 2023 Trevena 10-K; Updated all the patent related missing information in KDM and added related patent HEs; Here two patent related info and pending patent related countries are given according to application number they are updated
- 10 Apr 2023 Trevena has patent protection for compositions and methods of use of TRV 734 for treating drug abuse in Israel, Japan, and South Korea
- 10 Apr 2023 Trevena has patent protection for compositions and methods of use of TRV 734 in Macau before April 2023